Keywords: UK, NICE, Multiple sclerosis, Avonex, Betaferon, Rebif, Copaxone, Tysabri

UK Department of Health’s “money back” deal for MS drugs questioned; failing people with the disease

Article | 03 December 2009

Print This

In 2002, the UK’s National Institute for Clinical Excellence (NICE) ruled that certain drugs for the treatment of multiple sclerosis ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in